Description
The State of Michigan’s Department of Health and Human Services is issuing a sole‑source invitation to negotiate with Mayo Medical Laboratories (MML) for second‑tier newborn screening (NBS) testing on dried blood spots. The contract will cover a comprehensive panel of metabolic and genetic analytes, requiring advanced mass‑spectrometry methods and expert interpretation. The agreement is for a minimum three‑year term with five optional one‑year extensions, and it is intended to be the exclusive source for these specialized tests throughout the contract period.
• Scope: Perform second‑tier testing for 13 specific analyte groups (e.g., 17‑hydroxyprogesterone, homocysteine, heparan sulfate, acid‑alpha glucosidase, etc.) on dried blood spots collected via Michigan’s newborn screening program.
• Services: Laboratory analysis, data interpretation, and reporting of results to MDHHS‑BOL.
• Volume: Anticipated to cover all newborns screened in Michigan (≈70,000 births per year).
• Contract Length: Minimum 3 years, with up to five 1‑year renewal options.
• Funding: Commodity code 94855 – Medical and Laboratory Services (Non‑Physician).
• Sole Source Justification: MML is the only provider capable of performing the full panel on dried blood spots with the required methodology and interpretation.
• Submission Requirements: Questions due 10/28/2026; response to sole‑source challenge due 11/2/2026.